Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-11-12Clinical Trial Update: Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia [NA]
Clinical trial evaluating goal-directed therapy to prevent preeclampsia in high-risk pregnant women has completed.
-
CLINICAL_TRIALS trial_result · 2012-11-09Clinical Trial Update: Effect of Obesity on Long-term Clinical Outcomes After Kidney Donation
Completed clinical trial evaluating the impact of obesity on long-term outcomes after kidney donation.
-
FDA approval · 2012-11-08FDA Approved: BENAZEPRIL HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for benazepril hydrochloride from Aurobindo Pharma Limited. Benazepril hydrochloride is a generic AC…
-
FDA approval · 2012-11-08FDA Approved: BENAZEPRIL HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for Benazepril hydrochloride from Amneal Pharmaceuticals of New York LLC.
-
FDA approval · 2012-11-08FDA Approved: BENAZEPRIL HYDROCHLORIDE — Supplemental Application (Solco healthcare U.S., LLC)
The FDA approved a supplemental application for benazepril hydrochloride tablets from Solco Healthcare U.S., LLC, enabling the generic produ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-11-06Clinical Trial Update: Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension [Phase 1]
Phase 1 trial evaluating renal denervation in end-stage renal disease patients with refractory hypertension has completed.
-
FDA label_change · 2012-10-31FDA Approved: ZESTRIL — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for Zestril (lisinopril) from Upsher-Smith Laboratories, resulting in updated labeling.
-
FDA approval · 2012-10-31FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for the fixed-dose combination of amlodipine besylate and atorvastatin calcium, manufactured by …
-
FDA approval · 2012-10-31FDA Approved: ZESTORETIC — Supplemental Application (Almatica Pharma Inc.)
The FDA approved a supplemental application for ZESTORETIC (lisinopril and hydrochlorothiazide) from Almatica Pharma Inc., under NDA 019888.
-
FDA approval · 2012-10-31FDA Approved: TENORETIC — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for Tenoretic (atenolol and chlorthalidone) submitted by Upsher-Smith Laboratories.
-
CLINICAL_TRIALS trial_result · 2012-10-31Clinical Trial Update: Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus [Phase 4]
Phase 4 trial comparing aliskiren plus valsartan versus valsartan alone in patients with stage II systolic hypertension and type 2 diabetes;…
-
CLINICAL_TRIALS trial_result · 2012-10-31Clinical Trial Update: Proseal Laryngeal Mask Airway or Endotracheal Tube for Emergence From Neuroanesthesia [NA]
This clinical trial update notes a completed study comparing Proseal Laryngeal Mask Airway versus Endotracheal Tube for emergence from neuro…
-
CLINICAL_TRIALS trial_result · 2012-10-30Clinical Trial Update: Acute Carotid Sinus Endovascular Stimulation II Study [Phase 1]
Clinical trial update for Medtronic's Acute Carotid Sinus Endovascular Stimulation II Study (Phase 1) in hypertension; the study has complet…
-
CLINICAL_TRIALS trial_result · 2012-10-30Clinical Trial Update: Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism [NA]
This completed clinical trial evaluated the effects of sildenafil in resistant hypertension and explored genetic polymorphisms.
-
FDA label_change · 2012-10-26FDA Approved: AVALIDE — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA supplemental application for AVALIDE (irbesartan and hydrochlorothiazide) submitted by Sanofi-Aventis U.S. LLC, typically for labeling u…
-
CLINICAL_TRIALS trial_result · 2012-10-25Clinical Trial Update: Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial [NA]
A completed pragmatic trial focused on reducing clinical inertia in hypertension treatment.
-
FDA approval · 2012-10-24FDA Approved: MICARDIS HCT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for MICARDIS HCT (telmisartan and hydrochlorothiazide) submitted by Boehringer Ingelheim Pharmac…
-
CLINICAL_TRIALS trial_result · 2012-10-24Clinical Trial Update: Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients [Phase 3]
Phase 3 trial evaluating device-guided breathing exercises to reduce blood pressure in adults with hypertension and type 2 diabetes has comp…
-
CLINICAL_TRIALS trial_result · 2012-10-22Clinical Trial Update: Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients [Phase 4]
Phase 4 clinical trial update reporting results of aliskiren in elderly patients with hypertension and chronic kidney disease; the study has…
-
CLINICAL_TRIALS trial_result · 2012-10-22Clinical Trial Update: Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg) [Phase 3]
Phase 3 trial in Japan comparing telmisartan/amlodipine combination doses (80/5 mg vs 40/5 mg) in hypertension; results have been posted.
-
EMA withdrawal · 2012-10-22EMA Lapsed: Imprida HCT (amlodipine;valsartan;hydrochlorothiazide) — Novartis Europharm Ltd.
The EMA lists Imprida HCT (amlodipine; valsartan; hydrochlorothiazide) as lapsed, with hypertension as the therapeutic area.
-
FDA approval · 2012-10-15FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a generic fixed-dose combination of irbesartan and hydrochlorothiazide (IRBESARTAN AND HYDROCHLOROTHIAZIDE). The approval was i…
-
FDA approval · 2012-10-15FDA Approved: IRBESARTAN — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' original ANDA for Irbesartan, a generic angiotensin II receptor blocker for hypertension.
-
FDA approval · 2012-10-15FDA Approved: IRBESARTAN — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original ANDA for irbesartan, a generic angiotensin II receptor blocker for hypertension and …
-
CLINICAL_TRIALS research · 2012-10-15Clinical Trial Update: Genetic Determinant of Blood Pressure Sensitivity to Salt Intake [NA]
Clinical trial NCT01706887, funded by Assistance Publique - Hôpitaux de Paris, investigated genetic determinants of blood pressure sensitivi…